MASTER SERVICES AGREEMENT
Exhibit 10.38
THIS MASTER SERVICES AGREEMENT (“Agreement”) is made and entered into effective
January 27th, 2005 (the “Effective Date”), by and between NURA, Inc. (hereinafter
“Nura”), having a place of business at 0000 Xxxxxxxx Xxxxxx, Xxxxxxx XX, 00000, XXX, and ComGenex,
Inc. (hereinafter “ComGenex” or “CGX), having a place of business at Zahony u 0, X-0000 Xxxxxxxx,
Xxxxxxx, altogether referred to as Parties.
WHEREAS, Nura is engaged in the discovery and development of active substances against
diseases of the central nervous system and is planning to outsource a specific project that
involves the molecular target of Phosphodiesterase enzyme 10 (“PDE10” or “PDE10a”) as described in
Appendix A, and
WHEREAS, ComGenex is engaged in the business of providing complex drug discovery services
including but not limited to molecular biology, protein expression, assay development and high
throughput screening, chemical research and analysis, chemistry consulting, chemical synthesis,
manufacturing of specialty chemical products, chemoinformatics and related services, and undertakes
such as an independent company, understanding that neither ComGenex nor its employees or agents
shall be considered an employee of Nura; nor a participant in any programs, insurance or other
benefits extended to Nura’s employees; and,
NOW, THEREFORE, in consideration of the mutual covenants set forth below, the Parties hereby
agree as follows:
A. ComGenex Services: ComGenex shall provide to Nura complex drug discovery research
services (“Services”), including as detailed above and as agreed upon in writing from time to time
by the parties and set forth in Appendix B for each such project (the “Projects”). The parties
acknowledge and accept that successful completion of all projects is not guaranteed but shall be
completed by ComGenex on a best efforts basis. Nura and ComGenex shall agree upon, and specify in
the Appendix B the parameters of the Projects, the compensation to be paid for the Services, and
the time frame in which the Services are to be provided, subject to the terms of this Agreement.
Such Services may include, but are not limited to, the following:
1. Molecular Biology Services: ComGenex shall provide to Nura at Nura’s request and as
described in Appendix B, cloning and protein expression, assay development, high throughput
screening, and protein structure determination.
2. Medicinal Chemistry Research Services: ComGenex shall provide to Nura at Nura’s
request advice on design and synthesis of organic compounds, and for the completion of the
manufacture of such organic compounds.
3. Technical Assistance: ComGenex shall provide to Nura, at Nura’s request synthetic
chemical research, chemical library preparation, hit/lead evolution and/or optimization chemistry,
analysis and analytical method development, process development and process optimization studies,
and manufacturing of specialty chemicals.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
4. Technical Consultations: ComGenex shall be available to Nura via telephone at such
times as are requested by Nura and are mutually agreeable to ComGenex for technical consultations
with Nura’s research and development personnel.
B. Specific Duties of ComGenex:
1. In assuming responsibility for undertaking this Agreement, ComGenex will, on a best efforts
basis:
a) Perform molecular biology, chemistry and complex drug discovery services including protein
expression, assay development, high throughput screening, medicinal chemistry, chemistry
consulting, synthetic chemical research, combinatorial chemical synthesis, hit/lead evolution and
optimization chemistry, process development and process optimization studies, and manufacturing of
specialty chemicals for any Projects entered into, as described in Appendix B attached hereto.
b) Provide technical consultation, technical assistance and product development assistance, as
defined, for any Projects entered into.
c) Develop or utilize existing analytical methods that will allow determination of the
identity and quantification of the purity of any compounds delivered.
d) Provide compounds in the time frame set forth in Appendix B attached hereto, and
immediately notify Nura if any delays are encountered.
2. In assuming responsibility for undertaking this Agreement, ComGenex will:
a) Interact with Nura’s scientists as is deemed by ComGenex reasonably necessary and
appropriate in the conduct of the Projects outlined in Appendix B.
b) Provide as part of the Project research reports to Nura describing the results upon the
completion of individual Projects.
C. Specific Duties of Nura: Nura will:
1. Provide assistance such as is deemed reasonable and appropriate by Nura in the conduct of a
fully integrated research project team effort.
2. Interact with and communicate with ComGenex reasonably and respond to all reasonable
requests to provide necessary and appropriate Project guidance.
3. Agree to pay ComGenex for the Services to be performed by ComGenex as set forth in the
schedule of payments as shown in Appendix C.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-2-
D. Term and Termination:
1. This Agreement shall commence on the Effective Date and shall terminate eighteen months
after the Effective Date; provided however that Nura may elect to extend this Agreement for up to
an additional 18 months by written notification to ComGenex. Extension of this Agreement shall be
subject to future written Agreement.
2. The representations and warranties contained in this Agreement, as well as those rights
and/or obligations contained in the terms of this Agreement which by their intent or meaning have
validity beyond the term hereof, including without limitation Sections D, E, H, and I hereof, shall
survive the expiration or termination of this Agreement.
E. Financials:
1. Nura will pay to ComGenex the amount set forth, and at the indicated times set forth in
Appendix C. Nura will pay to ComGenex a first installment to help to cover the running cost of
Projects (“Cost Coverage”), and Nura will pay a milestone fee (“Milestone Fee’) upon completion of
each individual subprojects — both as described in Appendix C.
2. The Cost Coverage component in each Project will be paid in monthly installments as listed
in the Appendix C. Unless otherwise agreed in writing by the parties, Nura will not be obliged to
pay any Cost Coverage beyond that specified in Appendix C, including those cases in which a project
is not completed within the period shown in Appendix B. However once a milestone is reached and
achieved, Nura shall pay the milestone fee (“Milestone Fee”) as set forth in Appendix C.
3. To cover the start and initiation of the Projects, Nura will pay a down-payment of [†]
within 15 days of the Effective Date. This down-payment will be credited using the following
payment schedule: Each invoice issued by ComGenex will be reduced by 25% until the down-payment is
fully eliminated, as described in Appendix C.
4. In addition to the above payment obligations Nura or any of its licensees will pay to
ComGenex the following development related milestone fees for any and each compounds, chemical
entity or active substance, specifically developed under this Agreement that enters preclinical or
clinical development or any of the above representing the therapeutically active part of an
experimental pharmaceutical product developed under this Agreement that enters preclinical or
clinical development. For clarity, for any single compound, chemical entity or active substance
that reaches the listed milestone below, the associated fee shall be paid only once to ComGenex, by
either Nura or a licensee of Nura, whichever shall achieve such milestone first.
[†]
|
[†] | |||
[†]
|
[†] | |||
[†]
|
[†] | |||
[†]
|
[†] | |||
[†]
|
[†] | |||
[†]
|
[†] |
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-3-
Royalty payment by Nura or any of its licensees will be due to ComGenex in the event of any
and each compound, chemical entity or active substance specifically developed under this Agreement
representing the therapeutically active part of a product is marketed by Nura and/or a licensee or
any other third party. The resulting royalty rate will be [†].
5. Outsourced projects that are outlined in Appendix D will be reimbursed to ComGenex by Nura.
These payments are in addition to the payments detailed in Appendix C.
6. Except as set otherwise all payments will be 15 days from the date of invoice.
Notices:
All notices associated with this Agreement shall be by first class mail or courier, addressed
to the respective parties as follows:
To ComGenex:
ComGenex, Inc.
Attn: Xxxxxx Xxxx, Xx.X. XXX
Xxxxxx x. 0.
Xxxxxxxx, Xxxxxxx H-1031
Attn: Xxxxxx Xxxx, Xx.X. XXX
Xxxxxx x. 0.
Xxxxxxxx, Xxxxxxx H-1031
To Nura:
Nura, Inc.
Attn: Xxxxxxx X. Xxxx, Ph.D., CEO
0000 Xxxxxxxx Xxxxxx
Xxxxxxx XX, 00000
Attn: Xxxxxxx X. Xxxx, Ph.D., CEO
0000 Xxxxxxxx Xxxxxx
Xxxxxxx XX, 00000
The above named persons are acting on behalf of their respective organizations and may be
changed on an as needed basis.
F. Assignment: This Agreement may not be assigned or otherwise transferred by either
party without the prior written consent of the other party, with such consent not to be
unreasonably withheld; provided, however, that Nura or ComGenex may, without such consent, assign
this Agreement and its rights and obligations hereunder to its Affiliates and parent corporations,
or in connection with the transfer or sale of all or substantially all of the business to which
this Agreement pertains, or in the event of its merger or consolidation or change in control or
similar transaction. Any purported assignment in violation of the preceding sentences shall be
void. Any permitted assignee shall assume all obligations of its assignee under this Agreement.
“Affiliate” shall mean any company which directly or indirectly controls or is controlled by or is
under common control with a party hereto by means of ownership of more than fifty percent (50%) of
the voting stock or similar interest in said company.
G. Safety: Each of the parties agrees that if it becomes aware of any safety hazard
relating to any compound supplied or developed under this Agreement that it shall promptly notify
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-4-
the other party with all information in its possession or control concerning such safety hazard.
Nura recognizes that the toxic effect of the compounds supplied or developed under this Agreement
is not known and it may be toxic or harmful to human health. Nura agrees to take reasonably
necessary precautions when handling such compounds. ComGenex will not be held responsible in any
form if after delivery of such compounds to Nura the compounds cause harmful effects to any of
Nura’s employees, contractors, consultants or any other parties.
H. Entire Agreement:
1. Except as provided herein with respect to the Appendices affixed hereto and the obligations
provided in the CONFIDENTIAL DISCLOSURE AGREEMENT dated as of December 13, 2004 between parties,
this Agreement represents the entire agreement of the parties with respect to the subject matter
hereof and supersedes all prior communications, understandings and agreements with respect thereto.
2. No waiver, change or modification of the provisions of this Agreement shall be effective
unless it is in writing and signed by a duly authorized officer of ComGenex and Nura. Additional
Appendices describing Projects in writing and signed by a duly authorized officer of ComGenex and
Nura shall constitute part of this Agreement.
I. Miscellaneous:
1. The Parties agree that from time to time they may make public announcement relating to the
collaboration, where certain information pertaining to the collaboration is disclosed in the form
of a press release, press conference, an announcement associated with trade show, or reports for
television or other media. No such public announcements are permitted under this Agreement without
the express written approval of the other party.
2. ComGenex represents and warrants that it will render the services hereunder in accordance
with prevailing high professional standards and will make all reasonable efforts to produce
consistently high levels of accuracy and expertise and to meet timetables set forth under this
Agreement, and as described in Appendices B and C for completion of services. ComGenex further
represents and warrants that ComGenex and any third party personnel assigned to perform services
under this Agreement shall, in the opinion of ComGenex, have the skills necessary to efficiently
perform such services and produce chemicals, data and/or reports, as the case may be, in a form and
of a quality reasonably suitable to Nura.
3. ComGenex is an independent company and nothing in this Agreement shall be construed to
create a partnership, joint venture or employment relationship between the parties.
4. If any provision hereof shall be determined to be invalid or unenforceable, such
determination shall not affect the validity of the other provisions of this Agreement.
5. This Agreement shall be governed in accordance with the laws of the State of Washington,
USA, without regard to the conflicts of law provisions thereof.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-5-
6. Waiver by either party or the failure by either party to claim a breach of any provision of
this Agreement shall not be deemed to constitute a waiver or estoppel with respect to any
subsequent breach of any provision hereof.
7. If any dispute arises with regard to the performance of this contract by either party, a
good faith effort will be made by the parties to resolve such dispute by negotiation. If the
parties fail to resolve the dispute through negotiation, each party shall have the right to pursue
any other remedies legally available to resolve the dispute. The substantially prevailing party in
any proceeding conducted to interpret or enforce this Agreement shall be entitled to be reimbursed
by the other party for its reasonable attorneys’ fees and costs.
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives as of the date first written above.
| COMGENEX, INC. | NURA. INC. | |||||||
By:
|
/s/ Xx. Xxxxxx Urge | By: | /s/ Xxxxxxx X. Xxxx | |||||
Name:
|
Laszlo Urge | Name: | Xxxxxxx X. Xxxx | |||||
Title:
|
CEO, Director | Title: | CEO | |||||
Date:
|
07 Feb 2005 | Date: | 27 Jan 2005 | |||||
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-6-
Appendix A
To that certain Master Services Agreement by and between Nura Inc., and ComGenex Inc.
Materials Provided by Nura to ComGenex
[†]
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†]
|
[†] | |
[†] |
||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
| [†] | ||
[†] |
||
| [†] |
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
Appendix B
To that certain Master Services Agreement by and between Nura Inc., and ComGenex Inc.
To the extent that any term or provision set forth in this Appendix B is inconsistent with any
term or provision set forth in the Master Services Agreement, the Master Agreement shall be
controlling.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
Table of Contents
| MASTER SERVICES AGREEMENT | 1 | |||
| TABLE OF CONTENTS | 9 | |||
| OBJECTIVE | 11 | |||
| DEFINITIONS | 11 | |||
| BACKGROUND | 11 | |||
| PROJECT SUMMARY | 12 | |||
| MILESTONES | ||||
| SUBPROJECT 1: LEAD CANDIDATE GENERATION | 12 | |||
| SUBPROJECT 2: PROVISION OF HUMAN PDE10A. CLONING AND EXPRESSION | 12 | |||
| SUBPROJECT 3: ASSAY DEVELOPMENT, HTS | 12 | |||
| SUBPROJECT 4: COMPOUND OPTIMIZATION | 12 | |||
| TERMS | 13 | |||
| INTELLECTUAL PROPERTY RIGHTS | 13 | |||
| ANNEXES | 14 | |||
| ANNEX 1: DETAILED PROJECT PLAN | 14 | |||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| Subproject 1: Lead Candidate Generation | 20 | |||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| Subproject 2: Provision of human PDE10a. Closing and expression | 23 | |||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| Subproject 3: Assay development, HTS | 25 | |||
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| Subproject 4: Compound Optimization | 26 | |||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| [†] | ||||
| PAYMENTS | 35 | |||
| DOWN PAYMENT | 35 | |||
| COST COVERAGE PAYMENTS | 35 | |||
| MILESTONE FEES | 36 | |||
| Milestone 1 | 36 | |||
| Milestone 2 | 37 | |||
| [†] | 38 | |||
| Milestone 3 | 39 | |||
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-2-
Objective
The objective is to create a potent, selective PDE10a inhibitor with drug-like properties that
crosses the blood brain barrier. Potency should be less than [†] and selectivity greater than [†]
fold against other PDEs.
Definitions
| • | Patentable Lead Candidate |
Biologically active chemical entities, which are not covered by patent, and which may be
transformed into a clinically useful drug by subsequent modification/optimization.
| • | Focused library |
A set of compounds in silico selected or screened for binding preferably to a specific
biological target. The compounds are prepared by individual or parallel synthesis where the
building blocks are connected to each other in many possible variations.
| • | Advanced Lead |
Compounds that possess desired properties (potency, selectivity, physicochemical,
pharmacokinetic and toxicological characteristics) set by the Lead Criteria against the particular
target.
| • | Lead Criteria |
A set of criteria, mutually agreed to by the parties and included as Annex 3.
| • | Target |
The biological target (binding partner) of the lead compounds to be developed (PDE10a).
Background
Following the ongoing communication with Nura Inc., the above objectives were defined. In
order to achieve these objectives three parallel approaches were discussed:
[†]
[†]
[†]
According to the discussions the following division of responsibility was defined:
Nura responsibility:
[†]
[†]
[†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
ComGenex:
[†]
[†]
[†]
[†]
[†]
[†]
[†]
[†]
[†]
[†]
[†]
Project Summary
Subproject 1: Lead Candidate Generation
[†]
Subproject 2: Provision of human PDE1Oa. Cloning and expression
[†]
Subproject 3: Assay development, HTS
[†]
Subproject 4: Compound Optimization
[†]
Terms
Intellectual Property Rights
ComGenex shall retain no rights to any compound delivered to Nura. ComGenex shall have sole
ownership of all right, title, and interest in and to ComGenex patent rights and ComGenex
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-2-
technology as well as any invention arising from ComGenex’ platform or technology that are not
specific to the compounds or the related chemistry applied under this project.
No conflict
During the term of this Agreement, ComGenex will not participate in any program which has, as
its goal, the development of compounds which target PDE10.
[†] [Redaction continues for four pages]
Subproject 1: Lead Candidate Generation
[†] [Redaction continues for three pages]
Subproject 2: Provision of human PDE10a. Cloning and expression
[†] [Redaction continues for two pages]
Subproject 3: Assay development, HTS
[†] [Redaction continues for two pages]
Subproject 4: Compound Optimization
[†] [Redaction continues for three pages]
Annex 2: Definitions of the targeted Lead Criteria
Potent, selective PDE10a inhibitors with drug-like properties that cross the blood brain
barrier. [†]
The above definitions are subjected to change during the whole project upon agreement of the
Parties.
Annex 3: Initial Target information
cAMP and cAMP-inhibited cGMP 3’,5’-cyclic phosphodiesterase 10A (PDE10a) belongs to the cyclic
nucleotide phosphodiesterase family. It plays a role in signal transduction by regulating the
intracellular concentration of cyclic nucleotides. This enzyme can hydrolyze both cAMP and cGMP,
having a higher affinity for cAMP.
PDE10a is abundant in the putamen and caudate nucleus regions of brain and testis, it is
moderately expressed in the thyroid gland, pituitary gland, thalamus and cerebellum. The protein
is composed of a C-terminal catalytic domain containing two putative divalent metal sites and an
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-3-
N-terminal regulatory domain, which contains one putative cGMP-binding region. Several members of
the PDE family were crystallized and a there is a wide range of known substrates and inhibitors.
Annex 4: CGX’ Know-how
Genetic engineering, protein expression and renaturation.
At ComGenex we have extensive experience in genetic engineering and expressing sequences
across various expression systems. We have developed unique protein renaturation capabilities for
high yielding expression of functional proteins of your choice. We are active in the field of
assay development and high-throughput screening.
RefoldAll™ is modular protein production service from subcloning and fermentation to protein
purification, where renaturation is the key element of the process. With the integration of a
combinatorial approach and sophisticated parameter optimization, we offer fast and efficient
renaturation screens for your proteins.
XpressXpert™ is a comprehensive modular protein expression service which delivers purified
recombinant proteins according to client supplied DNA xxxxxxxx xxxx. We provide the following
discrete modules:
| • | cloning, subcloning | ||
| • | target oriented choice of expression system | ||
| • | protein expression in: E. coli, insect cells, mammalian cells | ||
| • | protein purification development | ||
| • | production scale-up |
Darvas F., Dorman G., Xxxx A., Urge L., Xxxxxx T., Borbola I., Xxxxxxx Z. and Ambrus G.
Development of a High-throughput Cytotoxicity Screening Method for Early Compound Filtering. 2004.
Society for Biomolecular Screening 10th Anniversary Conference and Exhibition, Orlando,
USA (September 11-15, 2004)
Narayan M., Xxxxxx E. and Scheraga H.A. 2003. Native Conformational Tendencies in Unfolded
Polypeptides: Development of a Novel Method To Assess Native Conformational Tendencies in the
Reduced Forms of Multiple Disulfide-Bonded Proteins. J. Am. Chem. Soc. 125 (8); 2036-2037.
Ambrus G., Gal P., Kojima M., Xxxxxxxx K., Balczer J., Antal J., Xxxx L., Xxxxx A., Xxxxxxx B.
E., Schwaeble W., Sim R. B. and Zavodszky P. 2003. Natural Substrates and Inhibitors of
Mannan-Binding Lectin-Associated Serine Protease-1 and -2: A Study on Recombinant Catalytic
Fragments. J. Immunol. 170, 1374-1 382.
Xxxxxx E., Narayan M., Xxxxxxxxx X. X. and Scheraga H. A. 2001. Structural determinants of
oxidative folding in proteins. PNAS, 98, 2312-2316.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-4-
Xxxxxx J., Gal P., Xxxxxxxx L., Thielens N. M., Xxxxxxxx K., Xxxxxxx Z., Xxxxxxx P., Xxxx L.,
Xxxxxx X. X. and Zavodszky P. 2001. The role of the individual domains in the structure and
function of the catalytic region of a modular serine protease, C1r J. Immunol 167, 5202-5208.
Scheraga H. A., Xxxxxxxxx, X. X. and Xxxxxx E. 2001. Bovine Pancreatic Ribonuclease A:
Oxidative and Conformational Folding Studies. Methods in Enyzmology, 341: 189-221.
XXXX™ -based analogue generation
ComGenex has developed a knowledge base and software with Xxxx. Xxxxxx Xxxxxx (Kyoto) for
bioanalogous lead evolution. The entry structures (validated hits, initial leads) are first
imported into our XXXX software to create the bioanalogous expansion of the chemical space defined
by the original hit molecules.
XXXX (Example Mediated Innovation for Lead Evolution) incorporates a knowledge base
(collection of structural “evolution” examples) and an interactive search engine. By analyzing
large number of biologically active compounds, several thousand structural “evolution” examples
(from simple bioisosteric structural replacements to bioanalogous drastic skeletal changes) were
identified and collected from literature into the XXXX database as virtual transformation rules.
The resulting candidate lead structures could exhibit improved pharmacological/ pharmacokinetic
characteristics, and help to reach novel intellectual property (IP) position.
Fujita T., Adachi M., Akamatsu M., Asao M. and Fukami H. Background and Features of XXXX, A
System for Database-aided Bioanalogous Structural Transformation of Bioactive Compounds. 1995.
QSAR and Drug Design: New Developments and Applications, Pharmacochemistry Library, Vol. 23 (Ed.
Fujita T), pp. 235-273. Elsevier, Amsterdam, 1995.
Xxxx A., Fujita T. and Darvas F. The implementation of an expert system for evolving
pharmaceutical leads. Xxxxxxxxx 0, Xxxxxxxx, July 1-5, 2001.
Darvas F, Fujita T. and Xxxx A. A Web-based Tool for Building Bioanalogous Libraries, DDJ
Japan, Tokyo, Jan 28, 2002.
XXXX™-Select™ for target family-based drug design
In the post-genomic drug discovery large enzyme families are investigated parallel in order
design selective inhibitors for many related isoforms in one combined research effort.
Chemogenomics is a bioinformatics-driven approach to explore the ligand-target knowledge space
based on the genetic (sequence homology) divergence of target family members.
This design approach identifies the major molecular determinants of the target-family
(privileged structures/ special recognition features) and virtual transformations leading
selectivity within the family. Using the knowledge base, which is an extension of the original
XXXX™ concept (XXXX-Select™) scaffolds or robust inhibitors can be transformed into selective
inhibitors (‘selectivity jumping’).
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-5-
Darvas F., Dorman G., Xxxx A., Szommer T., Ambrus G., Fujita T., Urge L. Novel chemogenomics
approach to design selective MMP inhibitors, Society for Biomolecular Screening 10th
Anniversary Conference and Exhibition, Orlando, USA (September 1115, 2004).
Darvas F., Dorman G., Xxxxxxx P., Xxxxxx L., Xxxxxx Z., Xxxxxxx Z. and Urge L. 2004. Recent
advances in chemical genomics. Curr. Med. Chem. (in press).
Lead Multiplier™ technology
ComGenex’ Lead Multiplier™ technology is designed to integrate proprietary chemoinformatics
tools in order to select, optimize and prioritize novel chemically distinct lead classes (de novo
focused libraries) against particular targets for hit validation and lead explosion.
The program utilizes a unique medicinal chemistry knowledge based expert system, a proprietary
similarity search tool, in silico pharmacokinetic filtering and diversity assessing methods. Lead
Multiplier™ Focused Library demonstrates pharmaceutically relevant structural complexity and at the
same time remains chemically distant from the original lead structures.
Successful applications:
Xxxxxx G, Xxxxxx-Xxxxx A, Xxxxxx G, Urge L, Xxxxxxx-Xxxxxxx M, Sziraki M. Bioanalogous
structure evolution for new lead generation. Design and discovery of novel dopamine transporter
inhibitors. ISMC2004, Copenhagen, August 15-1 9, 2004.
Patents:
Development of novel compounds for reversing Multi-Drug Resistance, (ComGenex with Solvo
Biotech), Xxxx Xxx Appl. P01-05401; 2001.
Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use
thereof. (ComGenex with Echelon Bioscience, Salt Lake City, UT, two joint patents filed in 2004
for two separate compound series, PCT 21958.PROV, PCT 21780.PROV).
CMT™ (ComGenex Matrix Technology)
ComGenex has developed its proprietary HT parallel chemistry platform, referred to as ComGenex
Matrix Technology (CMT™). It utilizes manual and robotized parallel synthesis stations of
different size that reflects the cascading diversity building approach. CMT™ is practically a
technological line that also contains state-of-the-art selection methods database management,
reaction piloting, HT purification and analytics.
Examples for successful application of CMT™:
Xxxxx L, Xxxx T, Xxxxxxx I, Xxxxx-Xxxxxxxx J, Xxxxxx D, Urge L. and Darvas F. 2003.
Solution-phase parallel synthesis of 4,6-diaryl-pyrimidine-2-ylamines and
2-amino-5,5-disubstituted-3,5-dihydro-imidazol-4-ones via a rearrangement, Tetrahedron, 59 (5)
655-662.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-6-
Xxxxxxxxx J., Xxxxx G., Xxxx T., Xxxxx O., Xxxxxx X., Urge L. and Darvas F. 2004. A
versatile procedure for the parallel preparation of 3-imidazo[l,2-a]pyridin-3-yl-propionic acid
derivatives involving Xxxxxxx’x acid, J. Comb. Chem. (in press).
Innovative chemical technologies:
—H-Cube: A microfluidics-based continuous flow hydrogenation device
This novel device, which is co-developed with Thales Nanotechnologies, (xxx.xxxxxxxxxx.xxx)
enables high-yield hydrogenation with improved selectivity.
Darvas F., Godorhazy L., Xxxxx G., Bucsai A. and Dorman G. Development and application of
microchannel flowreactor for parallel hydrogenation. ACS, Philadelphia, August 22-28, 2004.
Xxxxx R., Godorhazy L., Xxxxx G., Xxxxxx D., Xxxxxx X., Urge L. and Darvas F. A compact,
continuous flow device for high-pressure heterogeneous hydrogenation, J. Comb. Chem. (in press).
—MW: microwave heating
Integration of microwave heating into CMT enables to perform difficult chemical
transformations, multicomponent reactions that are typically carried out in low yield and long
reaction time.
Urge L. Integration of Microwave assisted chemistry into high-throughput chemistry platform.
The Pros and Cons. Conference on Microwave-Assisted Organic Synthesis, Boston, Nov. 11-13, 2004.
In silico ADME (BBB penetration, CNS likeness) prediction
ComGenex together with CompuDrug has developed a software family (Pallas™), which helps to
filter out, compounds early in the drug discovery pipeline, practically in the design phase. The
software allows the prediction of physicochemical parameters (pKa, LogP, LogD), metabolism, and
toxicity.
Darvas F., Keseru G., Xxxx A., Xxxxxx X., Urge I., Xxxxxxx P. 2002. In silico and Ex Silico
ADME Approaches for Drug Discovery, Current Topics in Medicinal Chemistry, 2, 1269-1277.
Dorman G. and Darvas F. 2002. HT Prediction, Virtual and Experimental Screening of Drug
Absorption, In: HT ADMETox estimation based on in vitro and in silico approaches, X. Xxxxx, G.
Dorrnan (Eds.), BioTechniques Press, Xxxxx Publishing, Westborough, MA, USA. 25-40pp.
Xxxxxx L.., Keseru G., Xxxx A., Xxxxxx Z. and Darvas F. 2004. A Neural Network Based
Prediction of Octanol-Water Partition Coefficients Using Atomic5 Fragmental Descriptors, Bioorg.
Med. Chem. Letters, 14(4), 851 -853
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-7-
ChemprobeTM tethering strategy
ComGenex has developed a novel tethering strategy where a representative subset is designed
around the core structure of known active compounds or combinatorial compound libraries with
appropriate terminal functional groups.
Dorman G., Xxxxxxxx D., Xxxxxx L., Urge L. and Damas F. Immobilized surrogate compound
libraries for rapid affinity profiling Eurocombi-2, Copenhagen, Jun 29-July 3,2003
Xxxxxxx L., Dorman G., Kele Z., Urge L., Damas F. and Xxxxxx L. 2003. Development of chemicaly
modified glass surfaces for nucleic acid, protein and small molecule microarrays, Mol. Div. 7,
25-36
FlashTag™ covalent labeling strategy
The major feature of covalent-bond forming libraries is a creation of a stable linkage between
small molecules and biopolymers targeted by the ligand or substrate toward the active site. As the
stable covalent linkage survives proteolysis, chemical fragmentation and sequencing, and the small
molecule trapped within the active site during the entire manipulation, this technique enables the
identification of the binding site. Combining with chemprobe™ combinatorial tethering approach the
architecture of the binding site can be investigated.
Dorman G. and Xxxxxxxxx X.X. 2000. Using Photolabile Ligands in Drug Discovery and
Development. Trends in Biotech. 18(2): 64-77
Dorman G., Xxxxxxx P. and Damas F. 2001. Chemical Library Approaches to Target Validation in
the Post-Genomic Era. Current Drug Discovery (October 2001), pp 00-00
Xxxxxx X. xxx Xxxxx X.0000. Utilizing small molecules in chemical genomics: toward HT
approaches, In: Chemical Genomics, Eds. Xxxxxx Xxxxxx, Andras Gut™ Gyogy Xxxxxx, Xxxxxx Xxxxxx, Xxx
Xxxx, Xxxxx, 0000, pp. 137-19 7
Diversity selection: the ED1 concept
ComGenex developed and employ for selection and library characterization a novel diversity
assessing approach, the Explicit Diversity Index (EDI). It combines structural dissimilarity and
core representativeness.
Xxxxxx-Xxxxx A., Dorman G., Xxxx A., Xxxxxx Z., Urge L. and Darvas F. Explicit Diversity Index
(EDI): A Novel Measure for Assessing the Diversity of Compound Databases, J. Chem. Inf Comp. Sci.
(in press)
Multiparametric QSAR approach
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-8-
Xxxxxx Xxxxxx developed a multiparametric QSAR design approach and successfully employed in
the area of CNS active drug design which lead to the development of deramciclane (The compound is
presently in Phase-IV at Orion, Pfizer — Pharmacia Upjohn.)
Darvas F., Xxxxxx A., Xxxxx Z. and Xxxxxx L. 1984. Computer Assisted Design of a Novel Type of
Tranquillant. QSAR and Strategies in the Design of Bioactive Compounds, 5th European Symp. on QSAR,
Bad Segeberg,l984 (Ed. Seydal JK), pp. 324-327. VCH, Weinheim, Germany.
Darvas F., Xxxxxx A., Xxxxx Z. and Xxxxxx L. 1984. Prediction of Therapeutical lndex for a
Novel Type of Tranquillant. QSAR in Toxicology and Xenobiochemistry, Bad Xxxxxxxx, Xxxxxxx,0000
(Ed. Xxxxx M), pp. 324-327. Elsevier, Amsterdam.
Parallel Lead Optimization Approach
The core of the ComGenex’ Parallel Lead Optimization Program is HT medicinal chemistry
supported by QSAR modeling and XXXX™ (example-Mediated Innovation for Lead Evolution). Other
supporting elements are: broad spectrum of in silico and in vitro ADMETox methods; complementing
with ADMETox prefiltered screening libraries; ActiVerse™, prescreened targeted libraries;
FlashTag™, a photomarker library for covalent protein tagging; HT Analytical services. ComGenex
integrated these approaches into a service package, allowing the R&D activities to proceed
simultaneously shortening the average preclinical development phase.
Xxxxxxx P., Xxxxxx X., Karancsi T., Xxxx A., Xxxxxx X., Xxxx T., Xxxxx I., Urge L. and Darvas
F. Parallel Lead Optimization Program Supported by EMlL Expert System — SBS, Den Xxxx, Sept
23-26,2002
Darvas F., Xxxxxxx P., Urge L., Dorman G., Karancsi T., Xxxx A., and Fujita T. Lead
Optimization Program with Parallel Design — DDJapan, Jan 28-31, 2002
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-9-
Confidential
Appendix C
To that certain Master Services Agreement by and between Nura Inc., and ComGenex Inc.
To the extent that any term or provision set forth in this Appendix C is inconsistent with any
term or provision set forth in the Master Services Agreement, the Master Agreement shall be
controlling.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
Payments
Down Payment
| Amount due | Amount to be paid | |
January 27, 2005
|
[†] |
Cost Coverage Payments
| Amount due | Amount billed | Amount to be paid | ||||||
Milestone 1 |
||||||||
February 15, 2005 |
[†] | [†] | ||||||
March 15, 2005 |
[†] | [†] | ||||||
April 15, 2005 |
[†] | [†] | ||||||
Subtotal |
[†] | |||||||
Milestone 2 |
||||||||
May 15, 2005 |
[†] | [†] | ||||||
June 15, 2005 |
[†] | [†] | ||||||
July 15, 2005 |
[†] | [†] | ||||||
August 15, 2005 |
[†] | [†] | ||||||
Subtotal |
[†] | |||||||
Milestone 3 |
||||||||
September 15, 2005 |
[†] | [†] | ||||||
October 15, 2005 |
[†] | [†] | ||||||
November 15, 2005 |
[†] | [†] | ||||||
December 15, 2005 |
[†] | [†] | ||||||
Subtotal |
[†] | |||||||
Total |
[†] | [†] | ||||||
Down Payment and Cost Coverage Payments are due within 15 days after receipt by Nura of the
appropriate invoice from ComGenex.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-2-
Milestone fees
Milestone Fee Payments are due within 15 days after receipt by Nura of the appropriate invoice
from ComGenex. Each invoice shall be accompanied by a report from ComGenex detailing the
particular tasks relating to the invoice and accomplished by ComGenex according to the “Project”
plan pursuant to Appendix B.
Milestone 1
| Subproject 1 | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| Subproject 2 | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-3-
Milestone 2
| Subproject 1 | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| Subproject 2 | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| Subproject 3 | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-4-
Optional items to Milestone 2
To be paid as Milestone Fee only (cost coverage is incorporated in the Milestone Fee).
Optional items to be performed only at the written request of Nura.
| Optional | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
The cost and the fee for the following optional items will be determined later
Preliminary biological screening
in vitro screening
| • | [†] |
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-5-
Milestone 3
| Subproject 3 | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| Subproject 4 | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-6-
Optional items to Milestone 3
To be paid as Milestone Fee only (costTo be paid as Milestone Fee only (cost coverage is
incorporated in the Milestone Fee).
Optional items to be performed only at the written request of Nura.
| Optional | If CGX delivers to Nura | Fee Due | ||
[†]
|
[†] | [†] |
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-7-
Confidential
Parties agree that the following costs will be reimbursed to ComGenex by Nura Inc:
1, Reasonable costs for obtaining commercially available recombinant PDE10a that is supplied to
facilitate early stage assay development. This cost incurs until sufficient amounts of recombinant
PDE10a from internal sources become available for assay development and screening.
2, If Nura requests optional selectivity screening as described in Appendix B; the costs of
selectivity studies to be performed on various PDE isotypes with ComGenex compounds.
3, If Nura requests real time PCR experiments, or other cell based assays that are not detailed in
Appendix B, the cost of these studies are borne by Nura.
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION |
-8-
